China's Akeso, hailed as biotech's ‘DeepSeek moment', falls despite nod for cancer drug
Shares of Chinese cancer drug developer Akeso slumped on Monday despite the company receiving a second marketing approval from the mainland's drug regulator for an innovative medicine.
Advertisement
The shares tumbled 10.2 per cent to HK$88.90 in the afternoon, after surging 20.8 per cent in the previous four sessions on the back of a string of favourable clinical trial results announcements. The shares traded as high as HK$105.50 on Friday, 6.5 times their
initial public offering price of HK$16.18 five years ago.
Guangzhou-based Akeso said in a statement to the Hong Kong stock exchange late on Sunday that the National Medical Products Administration had given it the go-ahead to market ivonescimab to treat certain non-small-cell lung cancer patients.
'This indication marks ivonescimab's second major approval,' the statement said, adding that the drug offered patients a safer ''chemotherapy-free'' alternative. Last May, regulators approved ivonescimab to treat non-squamous non-small-cell lung cancer patients.
Akeso founder and CEO Michelle Xia. Photo: Handout
The development of the new antibody drug was hailed by the mainland media last month as the biotech industry's '
DeepSeek moment ', as a clinical trial showed the treatment to be much more effective than a US-developed drug.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTHK
2 hours ago
- RTHK
'HK an ideal spot to raise funds for infrastructure'
'HK an ideal spot to raise funds for infrastructure' Finance chief Paul Chan says the SAR is moving fast to pioneer innovative financial models to attract more capital. Photo: RTHK Financial Secretary Paul Chan on Thursday said Hong Kong is well positioned to assist regions, especially those in the Global South, to raise funds to support large infrastructure projects. His remark came as the International Conference on Roads and Railways 2025 kicked off in Wan Chai, with some 30 speakers and panellists gathering to discuss the latest trends in the industry. Speaking at the event, Chan said the SAR is also moving fast to pioneer innovative financial models to attract more capital, such as the securitisation of infrastructure loans, a mechanism that transforms brownfield assets into investment products to support new greenfield projects. He noted that the city has already issued two such tranches totalling US$800 million to aid over 50 projects in the Middle East, Asia Pacific and Latin America, while its green bonds account for about half the total in Asia. "With a full suite of funding options, Hong Kong is where infrastructure projects from around the world could raise funds. This is particularly relevant for green and low-carbon infrastructure projects," he said. "In regions where the infrastructure funding gap remains urgent and significant, particularly in the Global South, Hong Kong offers practical and scalable ways to catalyse sustainable growth and accelerate the delivery of essential transport projects." Separately, the finance chief said the city is taking a lead in transit-oriented development (TOD), which refers to a planning approach that integrates high-density urban landscape with efficient public transport systems. Chan said the Northern Metropolis is a good example of TOD, with its Northern Metropolis Highway and the Northern Link set to drive housing and commercial services. He added that such an approach, if well-executed, can cut carbon emissions by up to 25 percent with the support of smart technology, such as EV charging networks and AI-optimised energy consumption. A site visit for conference participants will be organised on Saturday to showcase the city's featured road and railway projects, including the Central Kowloon Route and the Tung Chung Line Extension.
South China Morning Post
3 hours ago
- South China Morning Post
Australia ‘confident' Trump won't sink Aukus submarine deal after review
Australia's Defence Minister Richard Marles said on Thursday he was confident the Aukus submarine pact with the US and Britain would proceed, and his government would work closely with the US while the Trump administration conducted a formal review. Advertisement Australia in 2023 committed to spend A$368 billion (US$239 billion) over three decades on Aukus, the country's biggest-ever defence project with the United States and Britain, to acquire and build nuclear-powered submarines. A Pentagon official said the administration was reviewing Aukus to ensure it was 'aligned with the President's America First agenda', on the eve of expected talks between US President Donald Trump and Australian Prime Minister Anthony Albanese. In an Australian Broadcasting Corporation radio interview, Marles said Aukus was in the strategic interests of all three countries and the new review of the deal signed in 2021 when Joe Biden was the US president was not a surprise. 'I am very confident this is going to happen,' he said of Aukus, which would give Australia nuclear-powered submarines. Advertisement 'This is a multi-decade plan. There will be governments that come and go and I think whenever we see a new government, a review of this kind is going to be something which will be undertaken,' Marles told the ABC.
RTHK
5 hours ago
- RTHK
HK stocks down as investors gauge Sino-US trade deal
HK stocks down as investors gauge Sino-US trade deal Investors adopted a cautious attitude as details of the trade agreement between Beijing and Washington remain scarce. File photo: RTHK Hong Kong and mainland stocks fell on Thursday, led by declines in the rare-earth and tech sectors, as markets struggled to sustain positive momentum from Sino-US trade talks that provided few concrete details. A deal getting the fragile truce in the trade war back on track was reached after negotiators from Beijing and Washington agreed on a framework covering tariff rates, US President Donald Trump said on Wednesday. The deal removes Chinese export restrictions on rare-earths minerals and allows Chinese students access to US universities, but many specifics and detailed terms were absent, leaving investors cautious. China's blue-chip CSI300 Index fell 0.6 percent from a three-week high touched in the previous session. Hong Kong's benchmark Hang Seng index lost 0.7 percent to pull back from its highest level in nearly three months. The CSI Rare Earth Index slipped 0.8 percent from a seven-month high, and the semiconductor sector subindex slid more than 1 percent. In Hong Kong, the Hang Seng Tech Index lost 1.5 percent in early trades. (Reuters)
